secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2026-08-05T20:30:26+00:00
Accession:  0001654954-26-007306
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica Q2 revenue $9.5M (+37% YoY), net loss down 49% to $3.8M
----------------------------------------------------------------

- Record Q2 revenue of $9.5M, up 37% YoY; net loss reduced 49% to $3.8M from $7.4M.
- Diagnostics segment revenue grew 77% to $1.4M; Therapeutic Devices up 9% to $6.8M.
- Cash burn improved 38% to $3.4M; operating expenses down 20% to $10.1M.
- Cash and securities $44.1M; 22nd consecutive quarter of YoY revenue growth.
- Development Services segment contributed $1.4M in Q2, $3.4M YTD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495426007306/0001654954-26-007306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495426007306/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-26-007306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer